Vagifem is owned by Novo Nordisk Inc.
Vagifem contains Estradiol.
Vagifem has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Vagifem are:
Vagifem was authorised for market use on 26 March, 1999.
Vagifem is available in tablet;vaginal dosage forms.
Vagifem can be used as treatment of atrophic vaginitis due to menopause.
The generics of Vagifem are possible to be released after 17 September, 2022.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US7018992||NOVO NORDISK INC||Hormone composition|| |
(4 months ago)
Market Authorisation Date: 26 March, 1999
Treatment: Treatment of atrophic vaginitis due to menopause
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic